# US 2014/0234861 A1 · Method for diagnosis, prognosis or treatment of acute coronary syndrome (acs) comprising measurement of plasma concentration of macrophage migration inhibitory factor (mif)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0234861 A1
- Document ID: US20140234861A1
- Status: Published application
- Kind: A1
- Application number: 14/178,660
- Filed: 2014-02-12
- Published: 2014-08-21
- Earliest claimed: 2011-08-12
- Assignees: Alfred Health; Baker Idi Heart and Diabetes Institut Holdings Ltd.
- Applicants: Baker IDI Heart and Diabetes Institute Holdings LTD; Alfred Health
- Inventors: Anthony Dart
- Web page: https://patentgrep.com/patent/US20140234861A1

## CPC

- G01N 33/573: for enzymes or isoenzymes
- G01N 27/28: Electrolytic cell components
- G01N 33/6863: {Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors}
- G01N 2800/324: Coronary artery diseases, e.g. angina pectoris, myocardial infarction
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

A method for diagnosing acute coronary syndrome (ACS) in a subject, the method comprising measuring plasma macrophage migration inhibitory factor (MIF) concentration in a sample from the subject, and diagnosing ACS when the subject plasma MIF concentration is greater than a reference plasma MIF concentration, wherein the sample is taken less than 4 hours after symptom onset. The invention also relates to a method for prognosing ACS in a subject, the method comprising measuring plasma MIF concentration in a sample from the subject, diagnosing ACS when the subject plasma MIF concentration is greater than a reference plasma MIF concentration, and prognosing the magnitude of ACS from the subject plasma MIF concentration. Also provided is a method of treating ACS in a subject, a device, a kit, and a cardiac biomarker related to the methods of diagnosing and prognosing ACS.

## Claims

### Claim 1

A method for diagnosing acute coronary syndrome (ACS) in a subject, the method comprising measuring plasma macrophage migration inhibitory factor (MIF) concentration in a sample from the subject, and diagnosing ACS when the subject plasma MIF concentration is greater than a reference plasma MIF concentration, wherein the sample is taken less than 4 hours after symptom onset.

### Claim 2 (depends on 1)

The method of claim 1, further comprising prognosing the magnitude of ACS from the subject plasma MIF concentration.

### Claim 3

A method for prognosing ACS in a subject, the method comprising measuring plasma MIF concentration in a sample from the subject, diagnosing ACS when the subject plasma MIF concentration is greater than a reference plasma MIF concentration, and prognosing the magnitude of ACS from the subject plasma MIF concentration.

### Claim 4 (depends on 3)

The method of claim 3, comprising measuring plasma MIF concentration of the subject in a sample taken less than 4 hours after symptom onset.

### Claim 5 (depends on 1)

The method of claim 1, comprising measuring plasma MIF concentration of the subject in a sample taken 3 hours or less, 2 hours or less, 1 hour or less, or 30 minutes or less after symptom onset.

### Claim 6 (depends on 3)

The method of claim 3, comprising measuring plasma MIF concentration of the subject in a sample taken 3 hours or less, 2 hours or less, 1 hour or less, or 30 minutes or less after symptom onset.

### Claim 7 (depends on 1)

The method of claim 1, wherein the reference plasma MIF concentration is 1.4 μg/L or greater.

### Claim 8 (depends on 3)

The method of claim 3, wherein the reference plasma MIF concentration is 1.4 μg/L or greater.

### Claim 9 (depends on 1)

The method of claim 1, wherein ACS is acute myocardial infarction (AMI).

### Claim 10 (depends on 3)

The method of claim 3, wherein ACS is acute myocardial infarction (AMI).

### Claim 11 (depends on 9)

The method of claim 9, wherein the AMI is ST elevation myocardial infarction (STEMI) or non-ST elevation myocardial infarction (non-STEMI).

### Claim 12 (depends on 10)

The method of claim 10, wherein the AMI is ST elevation myocardial infarction (STEMI) or non-ST elevation myocardial infarction (non-STEMI).

### Claim 13 (depends on 3)

The method of claim 3, wherein ACS is AMI, the magnitude of ACS is infarct size expressed as a percentage at 3 days after AMI, and infarct size is prognosed from the correlation:
Infarct size at 3 days (%)=6.7×admission plasma MIF concentration (μg/L)+3.0.

### Claim 14 (depends on 3)

The method of claim 3, wherein ACS is AMI, the magnitude of ACS is infarct size expressed as a percentage at 3 months after AMI, and infarct size is prognosed from the correlation:
Infarct size at 3 months (%)=5×admission plasma MIF concentration (μg/L)+1.3.

### Claim 15 (depends on 1)

The method of claim 1, further comprising measuring the subject's plasma myoglobin, plasma troponin or plasma creatine kinase concentration.

### Claim 16 (depends on 3)

The method of claim 3, further comprising measuring the subject's plasma myoglobin, plasma troponin or plasma creatine kinase concentration.

### Claim 17 (depends on 15)

The method of claim 15, wherein MIF and any one or more of myoglobin, troponin or creatine kinase concentrations are measured in the same plasma sample.

### Claim 18 (depends on 16)

The method of claim 16, wherein MIF and any one or more of myoglobin, troponin or creatine kinase concentrations are measured in the same plasma sample.

### Claim 19

A method of treating ACS in a subject, the method comprising:
(a) measuring plasma MIF concentration in a sample taken from the subject less than 4 hours after symptom onset, and diagnosing ACS when the subject plasma MIF concentration is greater than a reference plasma MIF concentration; or
(b) measuring plasma MIF concentration in the subject sample, diagnosing ACS when the subject plasma MIF concentration is greater than the reference plasma MIF concentration, and prognosing the magnitude of ACS from the subject plasma MIF concentration; and
(c) performing percutaneous coronary intervention (PCI) and/or fibrinolysis on the subject.

### Claim 20

A device or kit comprising means that measures plasma MIF concentration in a sample from a subject, for use in a method for:
(a) diagnosing ACS in the subject, the method comprising measuring plasma MIF concentration in the sample taken from the subject less than 4 hours after symptom onset, and diagnosing ACS when the subject plasma MIF concentration is greater than a reference plasma MIF concentration; or
(b) prognosing ACS in the subject, the method comprising measuring plasma MIF concentration in the sample, diagnosing ACS when the subject plasma MIF concentration is greater than a reference plasma MIF concentration, and prognosing the magnitude of ACS from the subject plasma MIF concentration.

### Claim 21 (depends on 20)

The device or kit of claim 20, wherein the means comprises an immunoassay or an anti-MIF antibody.

### Claim 22 (depends on 20)

The device of claim 20, comprising an electrochemical cell.

### Claim 23 (depends on 22)

The device of claim 22, wherein the electrochemical cell comprises non-coplanar electrodes.

### Claim 24 (depends on 20)

The device of claim 20, wherein the device is a point of care device.

### Claim 25 (depends on 20)

The device or kit of claim 20, further comprising means that measures plasma myoglobin, plasma troponin or plasma creatine kinase.
